Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Transcenta Holding Limited ( (HK:6628) ) has shared an update.
Transcenta provided an update on measures to resolve the auditor’s disclaimer of opinion linked to its 2025 annual report, detailing progress on liquidity mitigation and balance-sheet strengthening. The company is advancing negotiations with global and regional pharmaceutical partners and investors to license or co-develop its lead asset osemitamab (TST001) and to secure financing for a planned global Phase 3 trial in Claudin18.2-positive gastric and gastroesophageal junction cancer.
It is also pursuing out-licensing and financing deals for other pipeline assets, including an amendment with Eli Lilly that returns two preclinical assets for US$4 million while preserving the blosozumab (TST002) license. In parallel, Transcenta is seeking up to US$100 million in new funding by year-end through diversified channels and has monetized its HiCB bioprocessing platform via a non-exclusive licensing deal with EirGenix Inc., receiving upfront and milestone payments and retaining future royalty potential, which collectively aim to ease liquidity pressure and reassure stakeholders.
More about Transcenta Holding Limited
Transcenta Holding Limited is a Cayman Islands-registered biopharmaceutical company listed in Hong Kong that focuses on developing innovative biologics for oncology and other therapeutic areas. Its pipeline includes lead asset osemitamab (TST001) and multiple other antibody and biologic programs, with a growing emphasis on global and regional partnerships and technology out-licensing to support R&D and commercialization.
Average Trading Volume: 689,318
Technical Sentiment Signal: Sell
Current Market Cap: HK$503.1M
Learn more about 6628 stock on TipRanks’ Stock Analysis page.